DENYES NANCY 4

What Happened Nancy Denyes, General Counsel of aTYR Pharma (ATYR), had 2,687 restricted stock units (RSUs) vest and convert into 2,687 common shares on Feb 3, 2026. A portion of those shares — 1,118 — were sold in an open-market transaction on Feb 4, 2026 at $0.98 per share, generating proceeds of $1,091. The RSU conversion is reported as a derivative conversion at $0.00 (no cash consideration).

Key Details

• Transaction dates/prices:
  • Feb 3, 2026: RSUs vested and converted to 2,687 shares (conversion recorded at $0.00).
  • Feb 4, 2026: Open-market sale of 1,118 shares at $0.98 each; total proceeds $1,091.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • F1–F2: Shares came from RSUs granted Feb 3, 2022, converting 1:1.
  • F3: The sale was made to satisfy tax withholding on the partial vesting.
  • F4: These RSUs vest in four equal annual installments beginning Feb 3, 2023 and fully vest Feb 3, 2026; they include accelerated vesting upon a change of control.
• Filing timeliness: Report covers period ending Feb 3, 2026 and was filed Feb 4, 2026 — appears timely (not marked late).

Context

• The derivative entry reflects RSU vesting/conversion (not an option-purchase for cash). The immediate sale of a portion of the newly vested shares to cover taxes is common and typically considered routine rather than an investment signal.
• The sale amount is small ($1,091) and driven by tax withholding, so it should not be interpreted by itself as a strong buy/sell signal from management.